Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: lucinactant

« Back to Dashboard
Lucinactant is the generic ingredient in one branded drug marketed by Discovery Labs and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has forty-two patent family members in fourteen countries.

One supplier is listed for this compound.

Summary for Generic Name: lucinactant

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Drug Master File Entries: 0
Suppliers / Packaging: see list1

Clinical Trials for: lucinactant

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
Status: Terminated Condition: Respiratory Distress Syndrome, Newborn; Premature Birth; Bronchopulmonary Dysplasia

Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
Status: Completed Condition: Cystic Fibrosis

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
Status: Completed Condition: Respiratory Distress Syndrome

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA
Status: Recruiting Condition: Respiratory Distress Syndrome

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome
Status: Terminated Condition: Meconium Aspiration

Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants
Status: Terminated Condition: Respiratory Distress Syndrome

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old
Status: Completed Condition: Acute Hypoxemic Respiratory Failure

Trial to Assess the Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age
Status: Recruiting Condition: Respiratory Distress Syndrome

KL₄Surfactant Treatment in Patients With ARDS
Status: Terminated Condition: Acute Respiratory Distress Syndrome

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Discovery Labs
SURFAXIN
lucinactant
SUSPENSION;INTRATRACHEAL021746-001Mar 6, 2012DISCNNo5,407,914<disabled>YY <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: lucinactant

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Discovery Labs
SURFAXIN
lucinactant
SUSPENSION;INTRATRACHEAL021746-001Mar 6, 20125,407,914<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: lucinactant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,164,369 Pulmonary surfactant protein and related polypeptide<disabled in preview>
6,613,734 Peptides-containing liposomal surfactants<disabled in preview>
5,260,273 Pulmonary surfactant protein and related polypeptide<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lucinactant

Country Document Number Publication Date
Japan3459248Oct 20, 2003
World Intellectual Property Organization (WIPO)9849191Nov 05, 1998
European Patent Office0350506Jan 22, 1992
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc